Stockscreener 앱 받기
1.79
5.29%
0.09
시장 영업 전:
1.79
Inhibikase Therapeutics Inc 주식(IKT)의 최신 뉴스
Inhibikase enrolls first patient in phase 3 PAH trial - MSN
Inhibikase Enrolls First Patient in Phase 3 PAH Trial - MyChesCo
Inhibikase grants stock options to five new employees - MSN
First patient enrolled in Phase 3 trial of PAH treatment IKT-001 - Pulmonary Hypertension News
MACD Signal: What is the Moat Score of Inhibikase Therapeutics IncQuarterly Growth Report & Short-Term High Return Ideas - baoquankhu1.vn
IKT Stock Price, Quote & Chart | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill
Inhibikase Grants Stock Options to Five New Employees - MyChesCo
H.C. Wainwright reiterates Inhibikase stock rating on trial progress By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Inhibikase stock rating on trial progress - Investing.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension - Sahm
Inhibikase Therapeutics Begins Enrollment for PAH Drug Trial - National Today
Inhibikase Therapeutics Enrolls First Patient in Global Phase 3 IMPROVE-PAH Study for Pulmonary Arterial Hypertension Treatment 1 - Minichart
Inhibikase enrolls first patient in Phase 3 PAH drug trial By Investing.com - Investing.com South Africa
Inhibikase Therapeutics (IKT) Begins Key Phase 3 Trial Enrollmen - GuruFocus
Inhibikase Therapeutics Enrolls First Patient In Phase 3 Trial For Pulmonary Arterial Hypertension - marketscreener.com
Inhibikase Begins Pivotal Phase 3 Trial in PAH - TipRanks
Inhibikase enrolls first patient in Phase 3 PAH drug trial - Investing.com
Inhibikase Announces First Patient Enrolled in Global Phase 3 IMPROVE-PAH Trial of IKT-001 - TradingView — Track All Markets
First patient dosed in Inhibikase (IKT) global Phase 3 IMPROVE-PAH trial of IKT-001 - Stock Titan
Springer Publishing Company & Cashmere Announce Partnership to Bring Trusted Healthcare Education Content to AI Systems - Weekly Voice
First patient enters global late-stage trial for PAH drug IKT-001 - Stock Titan
Inhibikase grants stock options to new employees under inducement plan - MSN
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Inhibikase Grants Stock Options to New Employees Under Inducement Plan - MyChesCo
IKT Technical Analysis & Stock Price Forecast - Intellectia AI
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Inhibikase Therapeutics Announces Inducement Grants - National Today
Inhibikase Therapeutics Grants Inducement Shares to New Hires - National Today
HC Wainwright Has Optimistic Outlook of IKT Q1 Earnings - Defense World
Nocion Therapeutics Appoints Mark Iwicki To Board - citybiz
HC Wainwright Issues Positive Estimate for IKT Earnings - MarketBeat
Inhibikase Therapeutics (IKT) Receives a Buy from H.C. Wainwright - The Globe and Mail
Death Cross: What is the next catalyst for Inhibikase Therapeutics Inc2026 Update & Safe Capital Investment Plans - baoquankhu1.vn
Inhibikase Therapeutics, Inc. 2025 Annual Report: Pipeline, Intellectual Property, and PAH Drug Development Overview - Minichart
Inhibikase Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Inhibikase Therapeutics 10-K: Operating loss $51.97M, Net loss $48.26M, Interest income $3.72M - TradingView
Inhibikase (NASDAQ: IKT) pivots to PAH drug IKT-001 with Phase 3 trial and $115M raise - Stock Titan
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Inhibikase (NASDAQ: IKT) boosts cash as 2025 loss grows and PAH Phase 3 advances - Stock Titan
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity - The Manila Times
Press Release: Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity - Moomoo
Surprises Report: What is the Moat Score of Inhibikase Therapeutics IncQuarterly Performance Summary & Entry and Exit Point Strategies - baoquankhu1.vn
Inhibikase Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Short Interest Up 52.2% in February - MarketBeat
Aug Ideas: Does Inhibikase Therapeutics Inc stock benefit from AI growth2026 Retail & Low Drawdown Trading Techniques - baoquankhu1.vn
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Rating of "Buy" by Analysts - MarketBeat
Reviewing Athira Pharma (NASDAQ:LONA) and Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
2.69%
0.25%
자본화:
|
볼륨(24시간):